



JAN 08 2004

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.	APPLICATION NO.
		05033.0002.CPUS02	10/650,057
PTO FORM 1449		APPLICANT	
		Von Knebel Doeberitz, et al.	
		FILING DATE	GROUP
		August 26, 2003	Not Assigned

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SR	1.	2001/0039023	11.08.01	Schubert, Walter			
SR	2.	2002/0086288	07.04.02	Bird, et al.			
	3.						
	4.						
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	5.	EP 0 723 156	06.12.95	Europe			YES NO
	6.	WO 99/04238	14.07.98	PCT			
Y	7.	EP 1 217 377	05.12.01	Europe			
OTHER REFERENCES							
(Including Author, Title, Date, Pertinent Pages, Etc.)							
SR	8.	Geradts, et al., "Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Product p16 ^{INK4A} in Archival Human Solid Tumors: Correlation with Retinoblastoma Protein Expression", <i>Cancer Research</i> 55: 6006-11 (1995)					
	9.	Hirama, et al., "p16 (CDKN2/Cyclin-dependent Kinase-+ inhibitor/Multiple Tumor Suppressor-1) Gene Is Not Altered in Uterine Cervical Carcinomas or Cell Lines", <i>Modern Pathology</i> , 9(1) 26-31 (1996)					
	10.	Kelley, et al., "CDKN2 in HPV-Positive and HPV-Negative Cervical-Carcinoma Cell Lines", <i>Int. J. Cancer</i> , 63: 226-30 (1995)					
	11.	Kim, et al., "Absence of p15 ^{INK4B} and p16 ^{INK4A} Gene Alterations in Primary Cervical Carcinoma Tissues and Cell Lines with Human Papillomavirus Infection", <i>Gynecologic Oncology</i> , 70: 75-9 (1998)					
	12.	Kim, et al., "Underexpression of Cyclin-Dependent Kinase (CDK) Inhibitors in Cervical Carcinoma", <i>Gynecologic Oncology</i> , 71: 38-45 (1998)					
	13.	Klaes, et al., "Overexpression of p16 ^{INK4A} as a Specific Marker for Dysplastic and Neoplastic Epithelial Cells of the Cervix Uteri", <i>Int. J. Cancer</i> , 92: 276-284 (2001)					
	14.	Milde-Langosch, et al., "P16/MTS1 and pRB expression in endometrial carcinomas", <i>Virchows Arch</i> , 434: 23-8 (1999)					
Y	15.	Milde-Langosch, et al., "p16/MTS1 Inactivation in Ovarian Carcinomas: High Frequency of Reduced					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

11 7/20/06



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO. 05033.0002.CPUS02	APPLICATION NO. 10/650,057
APPLICANT Von Knebel Doeberitz, et al.	
FILING DATE August 26, 2003	GROUP Not Assigned

<i>SJR</i>		Protein expression Associated with Hyper-Methylation or Mutation in Endometroid and Mucinous Tumors", <i>Int. J. Cancer</i> , 79: 61-5 (1998)
<i>SJR</i>	16.	Nuovo, et al., "In situ detection of the hypermethylation-induced inactivation of the p16 gene as a early event in oncogenesis", <i>PNAS</i> , 96(22): 12754-9 (1999)
	17.	Sano, et al., "Expression Status of p16 Protein Is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital Lesions", <i>American Journal of Pathology</i> , 153(6): 1741-8 (1998)
	18.	Sáno, et al., "Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia", <i>Pathology International</i> , 48: 580-5 (1998)
	19.	Serrano, et al., "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4", <i>Nature</i> , 366: 704-7 (1993)
	20.	Shigemasa, et al., "p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma", <i>J. Soc. Gynecol Invest.</i> , 4(2): 95-102 (1997)
	21.	Shim, et al., "Profiling of Differentially Expressed Genes in Human Primary Cervical Cancer by Complementary DNA Expression Array", <i>Clinical Cancer Research</i> , 4: 3045-50 (1998)
	22.	Tam, et al., "Differential Expression and Cell Cycle Regulation of the Cyclin-dependent Kinase 4 Inhibitor p16 ^{INK4} ", <i>Cancer Research</i> , 54: 1816-20 (1994)
	23.	Wong, et al., "Methylation of p16 ^{INK4A} in primary gynecologic malignancy", <i>Cancer Letters</i> , 136: 231-5 (1999)
<i>Y</i>	24.	Wong, et al., "p16 ^{INK4} and p15 ^{INK4B} Alterations in Primary Gynecologic Malignancy", <i>Gynecologic Oncology</i> 65: 319-24 (1997)

11 7/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05033.0002.CPUS02	APPLICATION NO. 10/650,057
PTO FORM 1449		APPLICANT VON KNEBEL DOEBERITZ, M. et al.	
		FILING DATE August 26, 2003	GROUP 1643



 JUN 15 2006
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SR	1.	US 4,281,061	07-1981	Zuk et al.,			
	2.						
	3.						
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	4.						YES NO
	5.						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
SR	6.	He, et al., "Expression, Deletion And Mutation of p16 Gene in Human Gastric Cancer" <i>World J. of Gastroenterology</i> 7(4): 515-521 (2001)					
	7.	Myung, et al., "Loss Of p16 And p27 Is Associated With Progression Of Human Gastric Cancer" <i>Cancer Letters</i> 153:129-136 (2000)					
	8.	Nakao et al., "Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation" <i>British J of Cancer</i> 75(10):1410-1416, 1997					
	9.	O'Nions, et al., "p73 Is Over-Expressed In Vulval Cancer Principally As The Δ2 Isoform" <i>British J. Cancer</i> 85(10):1551-1556 (Nov 2001)					
	10.	Sano, et al., "Overexpression Of P16 And P14ARF Is Associated With Human Papillomavirus Infection In Cervical Squamous Cell Carcinoma And Dysplasia" <i>Pathology Int.</i> 52:375-383 (May 2002)					
	11.	Sherr, "The Ink4a/Arf Network In Tumor Suppression" <i>Nature Reviews Mol. Cell Bio</i> 2:731-737, (2001)					
	12.	Takeuchi, et al., "Altered p16/MTS1/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With The Prognosis of Squamous Cell Carcinoma of the Esophagus" <i>Clinical Cancer Research</i> 3:2229-2236, (1997)					
↓	13.	Tsujie, et al., "Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer" <i>Oncology</i> 58:126-136 (2000)					
	14.						
	15.						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1
7/20/06



LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05033.0002.CPUS02	APPLICATION NO. 10/650,057
PTO FORM 1449		APPLICANT	
		VON KNEBEL DOEBERITZ, M. et al.	
		FILING DATE August 26, 2003	GROUP 1643

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SIR	1.	US 2003/0157482	08-2003	Keesee et al.			
	2.	US 6,033,847	03-2000	Sherr et al.			
↓	3.	US 6,316,208	11-2001	Roberts et al.			
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	4.						YES NO
	5.						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.